FDA Staffer Now Says Noven Pharmaceuticals Inc. And Shire Pharmaceuticals ADHD Patch Approvable; Reversing Earlier Opinion; Noven Trading Halted Ahead Of FDA Meeting On Patch

GAITHERSBURG, Md., Dec 2 (Reuters) - An experimental patch was safe enough to treat children with attention deficit hyperactivity disorder (ADHD), a U.S. Food and Drug Administration staff scientist said on Friday, reversing his earlier opinion.

Back to news